Pro Medicus Ltd
PME
Company Profile
Business description
Pro Medicus is a healthcare IT company specializing in radiology imaging software. Its main product, Visage 7, is a clinical desktop application that radiologists use to view, enhance, and manipulate images from any device and make a diagnosis. Its main customers are US private academic hospitals. In fiscal 2022, Pro Medicus earned 79% of revenue in North America, 16% from Australia, and the remaining 6% in Europe.
Contact
450 Swan Street
RichmondVIC3121
AUST: +61 394298800
Sector
Healthcare
Stock type
Defensive
Industry
Health Information Services
Fiscal Year End
30 June 2025
Employees
75
Pro Medicus Ltd News & Analysis
stocks
Have big earnings season moves made way for opportunities?
We look at the biggest market reactions in our coverage and what our analysts think about the companies.
stocks
ASX earnings recap from last week
We heard from some of the heavy weights in the ASX 200 including CBA and CSL.
stocks
ASX growth darling wows again but looks expensive
Pro Medicus reported another strong set of results. It continues to trade at a lofty valuation.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,450.90 | 64.30 | -0.76% |
| CAC 40 | 7,234.57 | 7.59 | 0.11% |
| DAX 40 | 19,068.46 | 34.82 | 0.18% |
| Dow JONES (US) | 43,910.98 | 382.15 | -0.86% |
| FTSE 100 | 8,037.53 | 11.76 | 0.15% |
| HKSE | 19,823.45 | 23.43 | -0.12% |
| NASDAQ | 19,281.40 | 17.36 | -0.09% |
| Nikkei 225 | 38,721.66 | 654.43 | -1.66% |
| NZX 50 Index | 12,674.49 | 74.87 | -0.59% |
| S&P 500 | 5,983.99 | 17.36 | -0.29% |
| S&P/ASX 200 | 8,193.40 | 62.20 | -0.75% |
| SSE Composite Index | 3,439.28 | 17.31 | 0.51% |